Comparison of oral therapies of different Chinese patent medicines for post-radiotherapy stomatitis in cancer patients: systematic review and meta-analysis
Frontiers in Oncology · 19.11.2026 · 16
DOI: 10.3389/fonc.2026.2006315 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 19.11.2026. Verfasst von Yueyi Chen und 7 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Randomized controlled trials suggest that Chinese patent medicines may improve radiation-induced oral mucositis and reduce adverse events; however, their efficacy and safety have not been systematically synthesized.
Objective
To evaluate the clinical efficacy and safety of Chinese patent medicines for radiation-induced oral mucositis.
Methods
Seven databases (China National Knowledge Infrastructure, Wanfang, VIP, PubMed, Embase, Web of Science, and the Cochrane Library) were searched from inception to March 2025. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. A network meta-analysis was conducted, and the surface under the cumulative ranking curve was used to rank interventions.
Results
Nine randomized controlled trials involving 919 patients and 11 interventions were included. Heat-Clearing Throat-Soothing Formula ranked highest for overall clinical efficacy (SUCRA = 81.8%), whereas the Lonicera-Lilium Tablets ranked lowest (12.1%). Throat-Clearing Oral Liquid showed the greatest probability of pain relief (77.8%), compared with minimal effects in the control group (0.8%). Heat-Clearing Throat-Soothing Formula was most effective in reducing severe (grade three to four) oral mucositis (86.6%), while the control group ranked lowest (0.4%).
Conclusion
Chinese patent medicines appear more effective than control interventions for radiation-induced oral mucositis. Lonicera-Lilium Tablets, Throat-Clearing Oral Liquid, and Heat-Clearing Throat-Soothing Formula showed the most favorable profiles across outcomes. However, given limited evidence, larger high-quality randomized controlled trials are required to confirm these findings.
Zitieren
APA
Chen, Y., Zhao, H., Li, Z., Di, J., Xu, W., Zhou, Y., Xue, Y., & Jia, L. (2026). Comparison of oral therapies of different Chinese patent medicines for post-radiotherapy stomatitis in cancer patients: systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2006315
Vancouver
Chen Y, Zhao H, Li Z, Di J, Xu W, Zhou Y, et al. Comparison of oral therapies of different Chinese patent medicines for post-radiotherapy stomatitis in cancer patients: systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2006315
BibTeX
@article{Chen2026,
author = {Chen, Yueyi and Zhao, Honghu and Li, Zhenyu and Di, Jiajie and Xu, Wen and Zhou, Yucheng and Xue, Yongxing and Jia, Li},
title = {Comparison of oral therapies of different Chinese patent medicines for post-radiotherapy stomatitis in cancer patients: systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.2006315}
}
EUVIMED